Holen Sie sich die Stockscreener-App
3.85
11.24%
-0.51
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Invesco Ltd. Buys New Stake in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Friedreich's Ataxia Market Growth | Trends, Treatments & - openPR.com
Design Therapeutics reports positive outcomes from trial of DT-168 eye drops - Yahoo Finance
Design Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated' - marketscreener.com
Design Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025 - Nasdaq
Design Therapeutics (DSGN) Reveals Positive Phase 1 Trial Results for DT-168 | DSGN Stock News - GuruFocus
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy - The Manila Times
JPMorgan Chase & Co. Buys 48,528 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PR Newswire
Geode Capital Management LLC Purchases 3,090 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs - Business Wire
Biotech stocks jump as Makary outlines FDA vision, RBC comments - Baystreet.ca
Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025 - Nasdaq
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 - The Manila Times
Design Therapeutics Phase 1 Data Shows Promise for Novel FECD Eye Drop Treatment | DSGN Stock News - Stock Titan
Forget the Correction: 2 Artificial Intelligence Stocks That Are Still Worth Buying Anyway - The Globe and Mail
April 2025's Promising Penny Stocks - simplywall.st
Design Therapeutics names new Chief Medical Officer By Investing.com - Investing.com Canada
Design Therapeutics Names Chris Storgard as Chief Medical Officer - marketscreener.com
BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics - Business Wire
Design Therapeutics names new Chief Medical Officer - Investing.com Australia
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - The Manila Times
Breakthrough: Design Therapeutics Strengthens GeneTAC Pipeline with Elite Drug Development Expert as New CMO - Stock Titan
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors - The Manila Times
Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential - PNAS
R. W. Roge & Company Inc. Has $1.23 Million Stake in Microsoft Co. (NASDAQ:MSFT) - Defense World
American Century Companies Inc. Purchases 6,481 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Corebridge Financial Inc. Reduces Stock Position in Couchbase, Inc. (NASDAQ:BASE) - Defense World
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update - The Manila Times
Breakthrough: New Parkinson's Drug Shows Lasting Effects Even After Treatment Stops - Stock Titan
AI Proteins CEO Chris Bahl to Speak at TED Main Stage on Next-Generation Miniprotein Therapeutics - Business Wire
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting - BioSpace
Charles Schwab Investment Management Inc. Has $1.63 Million Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
New Clinical Trial Details: Gain's Innovative Parkinson's Treatment Heads to Major Conference - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Bank of New York Mellon Corp Sells 3,777 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
VantAI Launches Neo-1, the First AI Model to Rewire Molecular Interactions by Unifying Structure Prediction and Generation for Therapeutic Design - Yahoo Finance
Spinocerebellar Ataxias Pipeline 2025: Therapies, MOA - openPR.com
Wall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High? - MSN
Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets - The Manila Times
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why - MSN
ElevateBio taps Amazon’s genAI tools to design CRISPR therapeutics - Yahoo Finance
RBC Raises Price Target on Design Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Design Therapeutics (DSGN) to Release Earnings on Tuesday - Defense World
KODKodiak Sciences Inc. Latest Stock News & Market Updates - StockTitan
ALGSAligos Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Design Therapeutics provides corporate highlights, anticipated milestones - TipRanks
Design Therapeutics, Inc. SEC 10-K Report - TradingView
2.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):